Constantin-Cristian Topriceanu,Xiangpu Gong,Anna L Hansell et al.
Constantin-Cristian Topriceanu et al.
Mi Zhou,Ming-Jiao Liao,Li-Xue Yin
Mi Zhou
The 4 Longest Days [0.03%]
最长的四天时间
Michelle M Kittleson
Michelle M Kittleson
Less Heart Failure But No Improvement in Quality of Life in FINEARTS-HF: Why the Disconnect? [0.03%]
FINEARTS-HF研究困境：心衰减少了，生活质量为何没提高？
Gad Cotter,Beth A Davison,Deepak L Bhatt
Gad Cotter
Clinical Trial Perspective: Role and Interpretation of Responder Analyses Involving Patient-Reported Outcomes [0.03%]
临床试验述评：基于患者报告结果的应答分析的作用和解读
John A Spertus,Andrew J Sauer,Suzanne V Arnold et al.
John A Spertus et al.
Harlan M Krumholz
Harlan M Krumholz
Re-Evaluating Recurrent Events in Heart Failure Trials: Patterns, Prognostic Implications, and Analytical Improvements [0.03%]
心力衰竭试验中反复发生事件的再评价：模式、预后意义和分析改进
Audinga-Dea Hazewinkel,John Gregson,Stuart J Pocock et al.
Audinga-Dea Hazewinkel et al.
Analyses using repeat hospitalizations (HFHs) are common in heart failure trials and typically assume that such repeat events occur randomly over time. Also, many think that using repeat events enhances statistical power. This article chall...
Factor XI Inhibition for Prevention of Thromboembolism: Safe, But Efficacious? [0.03%]
因子XI抑制预防血栓形成：安全且有效吗？
Behnood Bikdeli
Behnood Bikdeli
Perioperative Management of Patients Taking Factor XI Inhibitors: Small Steps Toward a Giant Leap [0.03%]
血友病患者手术期间使用FXI抑制剂的管理：迈向重大突破的一步
James D Douketis,P Gabriel Steg,Suzanne C Cannegieter et al.
James D Douketis et al.
Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71 [0.03%]
长效第十一因子XI抑制与手术前后出血：AZALEA-TIMI 71试验分析结果
Siddharth M Patel,Robert P Giugliano,David A Morrow et al.
Siddharth M Patel et al.
Background: In AZALEA-TIMI 71 (A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared with Open-Label Rivaroxaban in Patients with Atrial Fib...
Randomized Controlled Trial
Journal of the American College of Cardiology. 2025 Jun 17;85(23):2288-2298. DOI:10.1016/j.jacc.2025.04.018 2025